Continuous manufacturing has been one of the most talked-about shifts in pharmaceutical production for years, but for many professionals it has remained more concept than reality. A recent workshop held in Brazil aimed to change that, giving participants from both industry and academia a chance to see the technology in action and understand what it could mean for their own work.
The event was organized around a single compelling question: what does truly continuous wet granulation and drying look like when applied to research, development, and small-scale production? The answer, as attendees discovered, is more practical and more accessible than many had assumed.
Manufacturing workshop puts continuous production on full display
The workshop brought together professionals from across the pharmaceutical sector to explore the capabilities of twin-screw granulation and continuous drying through a combination of technical presentations, real-world application examples, and live equipment demonstrations. Rather than relying solely on slides and theory, the format was designed to let the technology speak for itself.
At the center of the event was a continuous granulation and drying system built around a patented approach to quality-by-design manufacturing. Demonstrations showed how the system can support the development and production of small batches of tablets and other solid oral dosage forms, a capability that is increasingly valuable as pharmaceutical companies look for ways to move faster from the lab to the production floor.
Topics covered during the sessions ranged from the technical foundations of the process to scale-up strategies, specific application scenarios, and firsthand accounts from companies that have already integrated the technology into their operations. The mix of perspectives gave participants a layered understanding of not just how the system works but how it performs under real-world conditions.
Why continuous manufacturing is gaining ground in pharmaceutical production
The push toward continuous manufacturing in the pharmaceutical industry is being driven by several converging forces. Traditional batch processing, while reliable, can be slow, resource-intensive, and difficult to scale efficiently. Continuous processes offer a fundamentally different model, one in which raw materials move through each stage of production without interruption, reducing waste, improving consistency, and giving manufacturers greater visibility into what is happening at every step.
For research and development teams working with small batches, the advantages are particularly meaningful. The ability to produce smaller quantities under tightly controlled conditions without losing the insights needed for eventual scale-up is a significant asset. It allows scientists and engineers to gather more useful data earlier in the development process, which can accelerate timelines and reduce the cost of bringing a new product to market.
The workshop in Brazil underscored how much appetite there is for this kind of knowledge transfer. Attendance reflected genuine enthusiasm from professionals who are actively weighing how continuous manufacturing fits into their organizations and what it would take to implement it.
A collaboration that made the learning deeper
The success of the event owed much to the collaborative spirit behind it. Academic expertise brought by researchers from one of Brazil’s leading pharmaceutical science programs sat alongside practical knowledge from industry partners, creating a learning environment that felt genuinely well-rounded. That combination of theoretical rigor and applied experience is rarely easy to achieve in a single setting, and it appeared to be one of the things participants valued most.
As continuous manufacturing continues to mature as a technology and more companies move from pilot programs to full integration, events like this one are likely to play an important role in spreading knowledge, building confidence, and helping the broader pharmaceutical community understand what is genuinely possible. The momentum building around this approach suggests that the question for most organizations is no longer whether to adopt continuous manufacturing but when and how to do it in a way that makes the most sense for their specific needs and production goals.
